Skip to content

CYTOSORBENTS CORPORATION: 10-K filed 2024-03-15

What CYTOSORBENTS CORPORATION reported in its annual report filed 2024-03-15 (fiscal FY 2023): 51 published measures, 189 facts as tagged in accession 0001410578-24-000201.

This filing

Form
10-K (annual report)
Filed
2024-03-15
Fiscal period
fiscal FY 2023
Accession
0001410578-24-000201 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYTOSORBENTS CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-12-3153,260,634USD
At 2022-12-3163,231,530USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-12-3129,985,471USD
At 2022-12-3127,856,557USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-12-3123,275,163USD
At 2022-12-3135,374,973USD
At 2021-12-3162,578,197USD
At 2020-12-3179,215,579USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-12-3114,131,137USD
At 2022-12-3122,144,567USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-28,507,394USD365
2022-01-01 to 2022-12-31-32,812,583USD365
2021-01-01 to 2021-12-31-24,558,648USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-21,655,136USD365
2022-01-01 to 2022-12-31-28,234,282USD365
2021-01-01 to 2021-12-31-14,005,599USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-12-31538,115USD365
2022-01-01 to 2022-12-316,087,365USD365
2021-01-01 to 2021-12-313,641,248USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-12-3114,474,210USD365
2022-01-01 to 2022-12-314,959,642USD365
2021-01-01 to 2021-12-31715,199USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-936,236USD365
2022-01-01 to 2022-12-31-6,455,576USD365
2021-01-01 to 2021-12-31-4,281,261USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-12-31-282,505,272USD
At 2022-12-31-253,997,878USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-01-01 to 2023-12-3144,656,391shares365
2022-01-01 to 2022-12-3143,573,215shares365
2021-01-01 to 2021-12-3143,359,186shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-01-01 to 2023-12-3144,656,391shares365
2022-01-01 to 2022-12-3143,573,215shares365
2021-01-01 to 2021-12-3143,359,186shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-0.12USD/shares92
2023-01-01 to 2023-12-31-0.64USD/shares365
2023-07-01 to 2023-09-30-0.21USD/shares92
2023-04-01 to 2023-06-30-0.14USD/shares91
2023-01-01 to 2023-03-31-0.17USD/shares90
2022-10-01 to 2022-12-31-0.02USD/shares92
2022-01-01 to 2022-12-31-0.75USD/shares365
2022-07-01 to 2022-09-30-0.28USD/shares92
2022-04-01 to 2022-06-30-0.25USD/shares91
2022-01-01 to 2022-03-31-0.21USD/shares90
2021-10-01 to 2021-12-31-0.25USD/shares92
2021-01-01 to 2021-12-31-0.57USD/shares365
2021-07-01 to 2021-09-30-0.15USD/shares92
2021-04-01 to 2021-06-30-0.11USD/shares91
2021-01-01 to 2021-03-31-0.1USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-0.12USD/shares92
2023-01-01 to 2023-12-31-0.64USD/shares365
2023-07-01 to 2023-09-30-0.21USD/shares92
2023-04-01 to 2023-06-30-0.14USD/shares91
2023-01-01 to 2023-03-31-0.17USD/shares90
2022-10-01 to 2022-12-31-0.02USD/shares92
2022-01-01 to 2022-12-31-0.75USD/shares365
2022-07-01 to 2022-09-30-0.28USD/shares92
2022-04-01 to 2022-06-30-0.25USD/shares91
2022-01-01 to 2022-03-31-0.21USD/shares90
2021-10-01 to 2021-12-31-0.25USD/shares92
2021-01-01 to 2021-12-31-0.57USD/shares365
2021-07-01 to 2021-09-30-0.15USD/shares92
2021-04-01 to 2021-06-30-0.11USD/shares91
2021-01-01 to 2021-03-31-0.1USD/shares90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-813,739USD365
2022-01-01 to 2022-12-31-1,092,585USD365
2021-01-01 to 2021-12-31-736,003USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-12-3110,056,354USD
At 2022-12-3110,743,032USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-12-313,329,307USD365
2022-01-01 to 2022-12-313,423,517USD365
2021-01-01 to 2021-12-314,020,819USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-9,408,222USD92
2023-01-01 to 2023-12-31-31,209,253USD365
2023-07-01 to 2023-09-30-7,350,198USD92
2023-04-01 to 2023-06-30-6,559,237USD91
2023-01-01 to 2023-03-31-7,891,596USD90
2022-10-01 to 2022-12-31-6,356,356USD92
2022-01-01 to 2022-12-31-31,521,879USD365
2022-07-01 to 2022-09-30-9,017,338USD92
2022-04-01 to 2022-06-30-8,357,050USD91
2022-01-01 to 2022-03-31-7,791,135USD90
2021-10-01 to 2021-12-31-9,561,821USD92
2021-01-01 to 2021-12-31-22,744,745USD365
2021-07-01 to 2021-09-30-5,406,000USD92
2021-04-01 to 2021-06-30-4,924,733USD91
2021-01-01 to 2021-03-31-2,852,191USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-12-3125,702,823USD
At 2022-12-3133,759,691USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-12-3114,545,955USD
At 2022-12-319,714,552USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-12-313,802,170USD
At 2022-12-311,655,173USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-12-313,906,552USD
At 2022-12-314,390,533USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-12-316,057,072USD
At 2022-12-315,664,941USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-01-01 to 2023-12-3153,601,276USD365
2022-01-01 to 2022-12-3152,254,936USD365
2021-01-01 to 2021-12-3154,862,922USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-12-313,680,129USD
At 2022-12-313,461,586USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-10-01 to 2023-12-315,311,280USD92
2023-01-01 to 2023-12-3122,392,023USD365
2023-07-01 to 2023-09-305,606,866USD92
2023-04-01 to 2023-06-306,018,550USD91
2023-01-01 to 2023-03-315,455,327USD90
2022-10-01 to 2022-12-315,757,036USD92
2022-01-01 to 2022-12-3120,733,057USD365
2022-07-01 to 2022-09-303,617,377USD92
2022-04-01 to 2022-06-304,944,856USD91
2022-01-01 to 2022-03-316,413,788USD90
2021-10-01 to 2021-12-317,659,452USD92
2021-01-01 to 2021-12-3132,118,177USD365
2021-07-01 to 2021-09-307,297,470USD92
2021-04-01 to 2021-06-309,313,852USD91
2021-01-01 to 2021-03-317,847,403USD90

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-01-01 to 2023-12-3133,600,065USD365
2022-01-01 to 2022-12-3134,288,130USD365
2021-01-01 to 2021-12-3135,750,477USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-01-01 to 2023-12-3115,728,915USD365
2022-01-01 to 2022-12-3115,118,907USD365
2021-01-01 to 2021-12-3116,380,930USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-12-3154,240,265shares
At 2022-12-3143,635,715shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-12-3115,615,095USD
At 2022-12-3123,832,026USD
At 2021-12-3153,825,166USD
At 2020-12-3171,421,601USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-12-31305,196,874USD
At 2022-12-31287,000,021USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-12-31529,321USD
At 2022-12-312,329,195USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-12-3112,058,896USD
At 2022-12-3112,603,901USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-12-3113,270,295USD
At 2022-12-3113,250,944USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2023-12-315,042,857USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-12-3113,092,384USD
At 2022-12-3112,639,724USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-12-313,036,030USD
At 2022-12-311,896,692USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-12-313,958,603USD
At 2022-12-314,437,447USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-12-31497,627USD
At 2022-12-31850,630USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-12-311,834,485USD
At 2022-12-312,488,597USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2023-12-311,380,821USD
At 2022-12-311,516,772USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2023-12-313,705,671USD
At 2022-12-313,831,103USD
At 2021-12-314,069,166USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-29,321,133USD365
2022-01-01 to 2022-12-31-33,905,168USD365
2021-01-01 to 2021-12-31-25,294,651USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-30,307,268USD365
2022-01-01 to 2022-12-31-31,008,973USD365
2021-01-01 to 2021-12-31-22,298,985USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-10-01 to 2023-12-31-5,834,907USD92
2023-01-01 to 2023-12-31-28,507,394USD365
2023-07-01 to 2023-09-30-9,193,520USD92
2023-04-01 to 2023-06-30-6,153,084USD91
2023-01-01 to 2023-03-31-7,325,883USD90
2022-10-01 to 2022-12-31-766,128USD92
2022-01-01 to 2022-12-31-32,812,583USD365
2022-07-01 to 2022-09-30-12,200,837USD92
2022-04-01 to 2022-06-30-10,879,222USD91
2022-01-01 to 2022-03-31-8,966,398USD90
2021-10-01 to 2021-12-31-9,307,012USD92
2021-01-01 to 2021-12-31-24,558,648USD365
2021-07-01 to 2021-09-30-6,406,285USD92
2021-04-01 to 2021-06-30-4,677,530USD91
2021-01-01 to 2021-03-31-4,167,821USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-12-311,239,600USD365
2022-01-01 to 2022-12-31688,565USD365
2021-01-01 to 2021-12-31571,156USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-01-01 to 2023-12-311,888,120USD365
2022-01-01 to 2022-12-31-2,383,289USD365
2021-01-01 to 2021-12-31-2,549,906USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-12-31376,668USD365

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2023-01-01 to 2023-12-312,403,000USD365
2022-01-01 to 2022-12-312,935,000USD365
2021-01-01 to 2021-12-311,968,000USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31245,616USD365
2022-01-01 to 2022-12-311,288,422USD365
2021-01-01 to 2021-12-31-420,578USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31121,039USD365
2022-01-01 to 2022-12-31-945,352USD365
2021-01-01 to 2021-12-312,350,547USD365

Inspect the source

Entity
CYTOSORBENTS CORPORATION / CIK 0001175151
Captured
2026-09-20T07:44:44.168Z
SEC response SHA-256
8bb195ec858f16302b2a8454a5ffe3eff6c1e6cd0312136a64a7a2f621b86836

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175151.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))